Infectious diseases consultation reduces 30-day and 1-year all-cause mortality for multidrug-resistant organism infections

Open Forum Infectious Diseases

Volumn 5, Issue 3, 2018, Pages

  Burnham, Jason P ^a   Olsen, Margaret A ^a   Stwalley, Dustin ^a   Kwon, Jennie H ^a   Babcock, Hilary M ^a   Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infectious diseases consultation; Multidrug resistant organisms

Indexed keywords

CEFTAZIDIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; VANCOMYCIN;

ACINETOBACTER; ADULT; ALL CAUSE MORTALITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CLINICAL OUTCOME; COHORT ANALYSIS; CONSULTATION; ENTEROBACTERIACEAE; ENTEROCOCCUS; FOLLOW UP; HOSPITAL INFECTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

EID: 85051636354     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofy026     Document Type: Article

References (29)

1. Shu JC, Chia JH, Kuo AJ, et al. A 7-year surveillance for ESBL-producing Escherichia coli and Klebsiella pneumoniae at a university hospital in Taiwan: the increase of CTX-M-15 in the ICU. Epidemiol Infect 2010; 138:253-63.
2. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37:1288-301.
3. Arnaud I, Maugat S, Jarlier V, Astagneau P. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013. Euro Surveillance 2015; 20.
4. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
5. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 2013; 11:321-31.
6. Nathwani D, Raman G, Sulham K, et al. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2014; 3:32.
7. Burnham JP, Kwon JH, Olsen MA, Babcock HA, Kollef MH. Readmissions with multidrug resistant infections in patients with prior multidrug resistant infection. Infect Control Hosp Epidemiol 2018; 39:12-9.
8. Bai AD, Showler A, Burry L, et al. Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study. Clin Infect Dis 2015; 60:1451-61.
9. Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect 2015; 21:79-86.
10. Hamandi B, Husain S, Humar A, Papadimitropoulos EA. Impact of infectious disease consultation on the clinical and economic outcomes of solid organ transplant recipients admitted for infectious complications. Clin Infect Dis 2014; 59:1074-82.
11. Spec A, Olsen MA, Raval K, Powderly WG. Impact of infectious diseases consultation on mortality of cryptococcal infection in patients without HIV. Clin Infect Dis 2017; 64:558-64.
12. Tissot F, Calandra T, Prod'hom G, et al. Mandatory infectious diseases consultation for MRSA bacteremia is associated with reduced mortality. J Infect 2014; 69:226-34.
13. Turner RB, Valcarlos E, Won R, et al. Impact of infectious diseases consultation on clinical outcomes of patients with Staphylococcus aureus bacteremia in a community health system. Antimicrob Agents Chemother 2016; 60:5682-7.
14. Vogel M, Schmitz RP, Hagel S, et al. Infectious disease consultation for Staphylococcus aureus bacteremia - a systematic review and meta-analysis. J Infect 2016; 72:19-28.
15. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92.
16. CDC. Unusual Susceptibility Profiles Alert. http://www.cdc.gov/nhsn/pdfs/ gen-support/usp-alert-current.pdf. Accessed 19 July 2016.
17. Multidrug-resistant organism and Clostridium difficile infection (MDRO/ CDI) Module. http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_ CDADcurrent.pdf. Accessed 19 July 2016.
18. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
19. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty- Fifth Informational Supplement. CLSI document M100-S25 Vol. 25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
20. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083-107.
21. Faurot KR, Jonsson Funk M, Pate V, et al. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf 2015; 24:59-66.
22. Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281-7.
23. Guillamet CV, Vazquez R, Noe J, et al. A cohort study of bacteremic pneumonia: the importance of antibiotic resistance and appropriate initial therapy? Medicine (Baltimore) 2016; 95:e4708.
24. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 2015; 19:219.
25. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
26. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis 2014; 14:572.
27. Burnham JP, Burnham CA, Warren DK, Kollef MH. Impact of time to appropriate therapy on mortality in patients with vancomycin-intermediate Staphylococcus aureus infection. Antimicrob Agents Chemother 2016; 60:5546-53.
28. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-44.
29. Butler AM, Olsen MA, Merz LR, et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol 2010; 31:28-35.